Zobrazeno 1 - 10
of 12
pro vyhledávání: '"M. C. Christian"'
Autor:
E. L. Trimble, M. C. Christian
Publikováno v:
International Journal of Gynecologic Cancer. 18:26-28
On the basis of three large randomized phase III trials, the National Cancer Institute (NCI) issued a Clinical Announcement in January 2006 recommending that women with optimally debulked stage III ovarian cancer and their physicians consider a combi
Autor:
P. T. C. Ho, James M. Pluda, M. C. Christian, J. M. Sorensen, Bruce D. Cheson, Susan G. Arbuck
Publikováno v:
Annals of Oncology. 8:S119-S128
While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the mainstay of therapy. Several new chemotherapy agents, including puri
Autor:
P, Therasse, S G, Arbuck, E A, Eisenhauer, J, Wanders, R S, Kaplan, L, Rubinstein, J, Verweij, M, Van Glabbeke, A T, van Oosterom, M C, Christian, S G, Gwyther
Publikováno v:
Journal of the National Cancer Institute. 92(3)
Anticancer cytotoxic agents go through a process by which their antitumor activity-on the basis of the amount of tumor shrinkage they could generate-has been investigated. In the late 1970s, the International Union Against Cancer and the World Health
Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer
Autor:
V K, Kasturi, M P, Dearing, S C, Piscitelli, E K, Russell, G G, Sladek, K, O'Neil, G A, Turner, T L, Morton, M C, Christian, B E, Johnson, M J, Kelley
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(9)
The mammalian pulmonary toxin 4-ipomeanol (IPO) is activated by the cytochrome P450 system in bronchial Clara cells in animals. The resulting metabolites bind rapidly to macromolecules, producing localized cytotoxicity. IPO has in vitro and in vivo a
Autor:
W D, Figg, M C, Christian, R, Lush, C J, Link, P, Davis, E, Kohn, G, Sarosy, M L, Rothenberg, R B, Weiss, N, Ryan, J, Jacobs, E, Reed
Publikováno v:
Biopharmaceuticsdrug disposition. 18(4)
Preclinical data suggest that ormaplatin (tetrachloro-(dl-trans)-1, 2-diamminocyclohexaneplatinum) has substantial activity in cisplatin-resistant tumor models and may be less nephrotoxic than cisplatin. Based on these data we initiated a phase I cli
Publikováno v:
Seminars in oncology. 24(2)
The Division of Cancer Treatment, Diagnosis and Centers of the National Cancer Institute (NCI) has a large program in clinical cancer therapeutics development. It currently holds investigational new drug applications for nearly 200 agents with which
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 8
While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the main-stay of therapy. Several new chemotherapy agents, including pur
Publikováno v:
Seminars in oncology. 20(4 Suppl 3)
Basic questions regarding optimal dose and schedule of anticancer drug administration frequently persist long after regulatory approval and commercial availability of a drug. For paclitaxel (TAXOL), these questions were considered early in drug devel
Autor:
E K, Rowinsky, D A, Noe, D S, Ettinger, M C, Christian, B G, Lubejko, E K, Fishman, S E, Sartorius, M R, Boyd, R C, Donehower
Publikováno v:
Cancer research. 53(8)
4-Ipomeanol (IPO), a naturally occurring pulmonary toxin, is the first cytotoxic agent to undergo clinical development based on a biochemical-biological rationale as an antineoplastic agent targeted specifically against lung cancer. This rationale is
Autor:
S G, Arbuck, M C, Christian, J S, Fisherman, L A, Cazenave, G, Sarosy, M, Suffness, J, Adams, R, Canetta, K E, Cole, M A, Friedman
Publikováno v:
Journal of the National Cancer Institute. Monographs. (15)
Taxol is the first of a novel class of anticancer drugs, the taxanes. Taxol's unique effects include its ability to polymerize tubulin into stable microtubules in the absence of cofactors and to induce the formation of stable microtubule bundles. Dur